Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer
Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
A study to investigate which of two different tablet formulations of ODM-201 is best suited
for use in the further development of the compound in the treatment of metastatic
chemotherapy-naive castration-resistant prostate cancer. Patients successfully completing the
bioavailability study will be able to receive further treatment with the current capsule
formulation of ODM-201 until progression of their disease with the safety and tolerability of
ODM-201 being assessed throughout.